Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend use of Merck's recently approved RSV antibody drug for infants 8 months or younger whose mothers did not receive a preventive shot during pregnancy.

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9.